This study identifies an initial NOS1AP-binding compound and shows that it can alter a NOS1AP-containing protein complex in living cells, and provides a foundation for optimizing NOS1AP-directed compounds and developing delivery systems to enhance brain penetration, tumor-selective accumulation, and therapeutic exposure in future studies.
Abstract
Simple Summary Glioblastoma is an aggressive brain cancer for which new therapeutic targets and drug-delivery strategies are urgently needed. NOS1AP is a signaling protein associated with glioma-cell growth, but it has not previously been directly targeted for glioblastoma therapy. This study identifies an initial NOS1AP-binding compound and shows that it can alter a NOS1AP-containing protein complex in living cells. Experiments in two glioblastoma cell models demonstrated concentration-dependent reductions in viability, while normal human astrocytes were substantially less sensitive. The findings provide a foundation for optimizing NOS1AP-directed compounds and developing delivery systems to enhance brain penetration, tumor-selective accumulation, and therapeutic exposure in future studies.
Current advances on multi-specific immune cell engagers for brain tumor treatment are reviewed and novel insights into overcoming existing challenges are provided.
Daan A. Sluijter, Rianne van Garderen, Ilse van Haveren et al.· Neuro-Oncology· 0 citations
Prostate-specific membrane antigen is a transmembrane glycoprotein that is highly specific and overexpressed in prostate cancer cells, making it an effective target for theranostics. Despite significant progress in recent years with prostate-specific membrane antigen-targeting radiopharmaceutical therapies that show pr...
Yang Wang, Jane McKenzie, S. Sandhu· Journal of Nuclear Medicine· 1 citation
Future studies should prioritize molecularly informed patient stratification, rational combination strategies, and advanced nanocarrier-mediated delivery platforms to facilitate the clinical translation of small-molecule therapeutics for GBM.
Bing-Xia Huang, Yan Wang· International Journal of Mol...· 0 citations
Targeted cancer therapies for cancer treatment are at the forefront of cancer treatments. The identification of pathologic cell signaling pathways in cancer cells via precision medicine enables the development of new therapies to target the underpinning molecular changes within tumor cells. Applying these techniques to...
H. Newton, Beddome C. Allen· Exploration of Neuroscience· 0 citations
This review systematically outlines the mechanistic underpinnings of multiple major RCD subtypes in OC, with a focused summary of advances in innovative small-molecule compounds targeting these pathways, to provide novel insights and directions for precision therapy in OC.
Yu Liu, Z. Geng, Baofu Jia et al.· Frontiers in Cell and Develo...· 0 citations
This study confirms five cell surface proteins (CSPs) as potential therapeutic targets in GBM and demonstrates the value of three-dimensional GSC cultures as robust models for biomarker research and target assessment.
Anna Laurent, G. Cobraiville, A. Allard et al.· Journal of Proteome Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
